Spike S1 RBD (B.1.1.529 BA.1, Omicron Variant) (SARS-CoV-2) : ACE2 Inhibitor Screening Colorimetric Assay Kit

The Spike S1 RBD (B.1.1.529 BA.1, Omicron Variant) (SARS-CoV-2) : ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors or neutralizing antibodies of the interaction between the SARS-CoV-2 Spike S1 RBD (receptor binding domain) (B.1.1.529 BA.1, Omicron Variant) and human ACE2 (angiotensin-converting enzyme 2) . This kit comes in a convenient 96-well format, with Biotinylated-ACE2 (amino acids 18-740), purified Spike S1 RBD (B.1.1.529 BA.1, Omicron Variant), Streptavidin-HRP, and assay buffers for 100 reactions. The SARS-CoV-2 Spike S1 RBD (B.1.1.529 BA.1, Omicron Variant) protein included in the kit, provides a biologically relevant model for the investigation of SARS-CoV-2/ACE2 interaction.First, SARS-CoV-2 Spike S1 RBD (B.1.1.529 BA.1, Omicron Variant) is coated on a 96-well plate overnight. After washing and blocking, the protein is pre-incubated with an inhibitor or neutralizing antibody. Upon subsequent incubation with Biotin-ACE2, the plate is treated with Streptavidin-HRP. After a final wash, Colorimetric HRP substrate is added to produce color that can be measured using a UV/Vis spectrophotometer microplate reader. The colorimetric signal is proportional to the efficacy of the binding of Spike S1 RBD (B.1.1.529 BA.1, Omicron Variant) to ACE2.Interested in having us perform the screening and profiling of inhibitors or blocking antibodies? Visit ourCoronavirus Service page.

Product Specifications

Background

The COVID-19 pandemic is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) . The Spike glycoprotein is expressed on the surface of the virus as a trimer. Each Spike protein consists of two subunits, S1 and S2, and the S1 subunit contains the receptor binding domain (RBD) which recognizes and attaches to the ACE2 (angiotensin-converting enzyme 2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. SARS-CoV-2 Variant B.1.1.529 BA.1, also known as Omicron variant, was originally discovered in South Africa and became a global variant of concern. Drugs targeting the interaction between SARS-CoV-2 Spike protein and human ACE2 may offer some protection against viral infection.

Applications

Screening inhibitors of ACE2 binding to SARS-CoV-2 Spike S1 RBD (B.1.1.529 BA.1, Omicron Variant) .

Format

Catalog #NameAmountStorage101356Spike S1 RBD (B.1.1.529 BA.1, Omicron Variant), Avi-His-Tag (SARS-CoV-2) *5 µg-80°C100665ACE2, His-Avi-Tag, Biotin labeled *2 x 5 µg-80°C793113x Immuno Buffer 150 ml-20°C79728Blocking Buffer 250 ml+4°C79742Streptavidin-HRP10 µl+4°C79651Colorimetric HRP substrate10 ml+4°C79964Transparent 96-well microplate1Room Temp*The initial concentration of the proteins is lot-specific and will be indicated on the tube containing the protein.

Shipping Conditions

-80°C

Storage Conditions

This assay kit will perform optimally for up to 6 months from date of receipt when the materials are stored as directed.

Notes

General Considerations“Blank” Control:The “Blank” control is important to determine the background absorbance in the assay. We recommend doing these in duplicate.Troubleshooting GuideVisitbpsbioscience.com/assay-kits-faqfor detailed troubleshooting instructions. For all further questions, please email[email protected]